Last updated: July 17, 2026

Application No. 19/423,511

CHIMERIC NEUROTOXINS

Non-Final OA

Filed

Dec 17, 2025

Priority

May 05, 2016 — GB 1607901.4 +4 more

Examiner

DUFFY, PATRICIA ANN

Art Unit

1645

Tech Center

1600 — Biotechnology & Organic Chemistry

Assignee

Ipsen Biopharm Limited

OA Round

1 (Non-Final)

This examiner grants 53% of cases after interview

— +34.2% interview lift. A telephonic interview to clarify the technical implementation could significantly improve the outcome.

Based on 569 resolved cases, 2023–2026

Examiner Intelligence

DUFFY, PATRICIA ANN View full profile →

Grants 53% of resolved cases

Career Allowance Rate

300 granted / 569 resolved

-7.3% vs TC avg

Strong +34% interview lift

Without

With

+34.2%

Interview Lift

resolved cases with interview

Typical timeline

3y 7m

Avg Prosecution

43 currently pending

Career history

615

Total Applications

across all art units

Statute-Specific Performance

§101

2.0%

-38.0% vs TC avg

§103

46.7%

+6.7% vs TC avg

§102

17.1%

-22.9% vs TC avg

§112

31.7%

-8.3% vs TC avg

Black line = Tech Center average estimate • Based on career data from 569 resolved cases

Prosecution Timeline

Dec 17, 2025

Application Filed

Jun 05, 2026

Non-Final Rejection mailed (current)

Precedent Cases

Applications granted by this same examiner with similar technology

16/497,820

Patent 11771721

APPLICATIONS OF GENETICALLY ENGINEERED BACTERIA VNP20009-M IN PREPARATION OF DRUGS FOR PREVENTING AND TREATING LUNG CANCER

4y 0m to grant Granted Oct 03, 2023

16/852,697

Patent 11707529

IMMUNOGENIC GLYCOPROTEIN CONJUGATES

3y 3m to grant Granted Jul 25, 2023

16/329,367

Patent 11701384

METHODS AND COMPOSITIONS INVOLVING INTERLEUKIN-6 RECEPTOR ALPHA-BINDING SINGLE CHAIN VARIABLE FRAGMENTS

4y 4m to grant Granted Jul 18, 2023

16/478,821

Patent 11690919

ENDOLYSOSOMAL TARGETING CONJUGATES FOR IMPROVED DELIVERY OF CARGO MOLECULES TO THE ENDOLYSOSOMAL COMPARTMENT OF TARGET CELLS

3y 11m to grant Granted Jul 04, 2023

16/636,503

Patent 11690900

PROTEINS HAVING PNEUMOCOCCAL CAPSULE DEGRADING ACTIVITY AND METHODS OF USE

3y 5m to grant Granted Jul 04, 2023

Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.

Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2

Expected OA Rounds

53%

Grant Probability

87%

With Interview (+34.2%)

3y 7m (~3y 0m remaining)

Median Time to Grant

Low

PTA Risk

Based on 569 resolved cases by this examiner. Grant probability derived from career allowance rate.